Clonidine

LAMEA Attention Deficit Hyperactivity Disorder Market 2022: Featuring Eli Lilly, Pfizer, Johnson & Johnson, Novartis & More - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 11, 2023
Health, Pharmaceutical, DSM-IV, Caffeine, Amphetamine, Boston Children's Hospital, Hospital pharmacy, Guanfacine, Country, Safety, Methylphenidate, Hospital, Organization, Clonidine, Adderall, ADHD, Patient, Prevalence, Distribution, Pharmaceutical industry, Lisdexamfetamine

Nearly 65% of diagnosed children with ADHD have also continued to show the symptoms of the disorder well into adulthood.

Key Points: 
  • Nearly 65% of diagnosed children with ADHD have also continued to show the symptoms of the disorder well into adulthood.
  • This further suggested that ADHD can be regarded as a chronic developmental disorder in the nation.
  • The Brazil market dominated the LAMEA Attention Deficit Hyperactivity Disorder Market by Country in 2021; thereby, achieving a market value of $199.4 million by 2028.
  • Additionally, The UAE market would register a CAGR of 7% during (2022-2028).

Global Attention Deficit Hyperactivity Disorder Market Report 2022: Increasing Recognition of Behavioral Therapy Benefits Boosts Sector - ResearchAndMarkets.com

Retrieved on: 
Friday, January 6, 2023
Pharmaceutical, Health, Neurology, Dextroamphetamine, Electronic health record, Amphetamine, Anxiety, Health, Central nervous system, Bipolar disorder, Clonidine, Depression, Brain, Parent, Narcolepsy, CNS, Johnson & Johnson, Growth, Patient, Attention deficit hyperactivity disorder, Speech, Attention, Movement, ADHD, Attention deficit hyperactivity disorder predominantly inattentive, Guanfacine, Antisocial personality disorder, Pharmacy, SNRI, Laika (EHR testing framework), Methylphenidate, Toy, Pharmaceutical industry

Based on drug type, the attention deficit hyperactivity disorder market is categorized into stimulants and non-stimulants.

Key Points: 
  • Based on drug type, the attention deficit hyperactivity disorder market is categorized into stimulants and non-stimulants.
  • The stimulants segment procured the highest revenue share in the attention deficit hyperactivity disorder market in 2021.
  • The retail pharmacy segment recorded the largest revenue share in the attention deficit hyperactivity disorder market in 2021.
  • On the basis of region, the attention deficit hyperactivity disorder market is analyzed across North America, Europe, Asia Pacific, and LAMEA.

Clinical Research by Salem Anaesthesia Pain Clinic, Surrey, Canada, Shows That Clonidine is Better Than Zopiclone for Insomnia Treatment

Retrieved on: 
Wednesday, November 2, 2022
Patient safety, Health, Xerostomia, Gamma-Aminobutyric acid, Attention deficit hyperactivity disorder predominantly inattentive, Clonidine, Fatigue, Brain, Research, Hallucination, GLOBE, Hypertension, Drug, Insomnia, Safety, Nightmare, Anxiety, Amnesia, Bruxism, Journal, Patient, Mood disorder, Confusion, Benzodiazepine, Falls, Addiction, Headache, Depression, Chronic pain, Dentistry, Pharmaceutical industry

SURREY, British Columbia, Nov. 02, 2022 (GLOBE NEWSWIRE) -- A clinical research study has shown that Clonidine is better than Zopiclone for insomnia treatment in chronic pain patients.

Key Points: 
  • SURREY, British Columbia, Nov. 02, 2022 (GLOBE NEWSWIRE) -- A clinical research study has shown that Clonidine is better than Zopiclone for insomnia treatment in chronic pain patients.
  • The critically acclaimed research was led and authored by Dr. Olu Bamgbade at the Salem Anaesthesia Pain Clinic in Surrey, British Columbia, Canada.
  • Dr. Olu Bamgbade is the director of the Salem Anaesthesia Pain Clinic, a specialist pain clinic and research center( https://salempainclinic.net/ ).
  • Based in Surrey, British Columbia, Canada, Salem Anaesthesia Pain Clinic is aspecialist pain clinic and research center that provides multimodal pain management, interventional pain treatment, substance misuse therapy, insomnia treatment and preoperative optimization therapy.

Melinta Therapeutics Acquires U.S. Rights to TOPROL-XL® (metoprolol succinate) from New American Therapeutics

Retrieved on: 
Wednesday, April 6, 2022
Health, Infectious Diseases, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, Risk, Hypoglycemia, Therapy, Meropenem, First-degree atrioventricular block, Clonidine, Blood pressure, Cardiac arrest, NYHA, III, Allergy, Moyamoya disease, Diabetes, Angina, Diltiazem, Hyperthyroidism, Vaborbactam, Cardiogenic shock, AstraZeneca, Heart, Patient, Hypertension, Bradycardia, Peripheral artery disease, CEO, Adrenaline, Sinus node dysfunction, Pheochromocytoma, LLC, Heart block, Acquisition, Stroke, Verapamil, Injection, Castleman disease, Heart failure, Purkinje fibers, Digitalis, FDA, Minocycline, Infarction, Hypersensitivity, Pharmaceutical industry, Medical device, Melinta Therapeutics

We will continue to aggressively pursue portfolio expansion that aligns with our mission of providing innovative therapies for acute and life-threatening illnesses.

Key Points: 
  • We will continue to aggressively pursue portfolio expansion that aligns with our mission of providing innovative therapies for acute and life-threatening illnesses.
  • We are extremely proud of our work to provide access to this lifesaving medication, said Michael Anderson, CEO, New American Therapeutics.
  • Melinta Therapeutics, LLC provides innovative therapies to people impacted by acute and life-threatening illnesses.
  • At Melinta, were visionaries dedicated to innovation while staying grounded in what matters most: patients.

Monopar Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Program Developments

Retrieved on: 
Thursday, March 24, 2022
Company, Private Securities Litigation Reform Act, Life, Therapy, Clonidine, Cancer, Heart, CRT, Clinical trial, Chemoradiotherapy, IND, Research, SEC, Hydrogen chloride, Program, Observation, Oropharyngeal cancer, Doxorubicin, Food, Liu v. Securities and Exchange Commission, Mucositis, Drug discovery, Quality of life, Security (finance), G&A, NCT, COVID-19, Drug resistance, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, SOM, GLOBE, FDA, VOICE, Patient, Pharmaceutical industry, Medical imaging, Vaccine, Lithium, Verification and validation

WILMETTE, Ill., March 24, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced fourth quarter and full-year 2021 financial results and summarized recent program developments.

Key Points: 
  • Results for the Fourth Quarter and Year Ended December 31, 2021, Compared to the Fourth Quarter and Year Ended December 31, 2020
    Cash and cash equivalents as of December 31, 2021, were $20.3 million.
  • Net loss for the fourth quarter of 2021 was $2.7 million or $0.21 per share compared to net loss of $2.1 million or $0.19 per share for the fourth quarter of 2020.
  • R&D expenses for the fourth quarter of 2021 were $2.0 million compared to $1.6 million for the fourth quarter of 2020.
  • G&A expenses for the fourth quarter of 2021 were $0.7 million, compared to $0.6 million for the fourth quarter of 2020.

Aeterna Zentaris Provides Update on Ongoing Pivotal Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

Retrieved on: 
Monday, March 21, 2022
Company, Amyotrophic lateral sclerosis, Chlamydia trachomatis, Clonidine, NASDAQ, U.S. FDA, Diagnosis, Marketing, Risk, Forward-looking statement, Clinical trial, Toronto Stock Exchange, Arginine, Legislation, Adult, European Commission, ALS, PD, Neuromyelitis optica spectrum disorder, Parkinson's disease, Severe acute respiratory syndrome coronavirus 2, EudraCT, Growth hormone, TSX, Safety, Time, COVID-19, GLOBE, Union, Hypoparathyroidism, News, NMOSD, Annual report, FDA, Novo Nordisk, Patient, Pharmaceutical industry, Ludwig & Mayer

TORONTO, ONTARIO, March 21, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today provided an update for its ongoing pivotal Phase 3 safety and efficacy study AEZS-130-P02 (the “DETECT-trial") evaluating macimorelin for the diagnosis of childhood-onset growth hormone deficiency (CGHD).

Key Points: 
  • The DETECT-trial is a multicenter, open-label trial to investigate the efficacy and safety of a single oral dose of 1.0 mg/kg macimorelin acetate as growth hormone stimulation test (GHST) in pediatric patients with suspected growth hormone deficiency (GHD).
  • Children and adolescents from two to less than 18 years of age with suspected growth hormone deficiency are to be included.
  • The macimorelin GHST will be performed twice for repeatability data and two standard GHSTs will be used as controls: arginine (i.v.)
  • The Company's lead product, macimorelin (Macrilen), is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD).

Eton Pharmaceuticals and XGen Pharmaceuticals DJB Announce Commercial Launch of Rezipres® (ephedrine hydrochloride), a Ready-to-Use Formulation of Injectable Ephedrine (4.7 mg/mL)

Retrieved on: 
Monday, March 14, 2022
Hypertension, AmerisourceBergen, U.S. Securities and Exchange Commission, Therapy, Atropine, Degenerative disease, Private Securities Litigation Reform Act, Injection, Bradycardia, Bromide, Nervous, Oxytocin, Stroke, Growth, National, Intubation, New Drug Application, Carglumic acid, Safety, McKesson Corporation, Restless, Theophylline, FDA, Anesthesia, Tachyphylaxis, Temperature, Dizziness, Cardinal Health, MAOI, GLOBE, Nausea, Patient, Quinidine, Arrhythmia, Digitalis, Clonidine, XGen Studios, CEO, Ephedrine, Insomnia, Reserpine, Vomiting, Security (finance), Xanthine oxidase inhibitor, Ownership, Hypotension, Sulfite, Nasdaq, Incidence, Mephentermine, Guanethidine, Palpitations, Hospital, Tachycardia, Plasma protein binding, IQVIA, Goal, Pharmaceutical industry

DEER PARK, Ill., March 14, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON) and XGen Pharmaceuticals DJB, Inc. today announced the commercial availability of Rezipres (ephedrine hydrochloride) injection.

Key Points: 
  • DEER PARK, Ill., March 14, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON) and XGen Pharmaceuticals DJB, Inc. today announced the commercial availability of Rezipres (ephedrine hydrochloride) injection.
  • Rezipres (4.7 mg/mL) is a ready-to-use1 formulation of injectable ephedrine hydrochloride that is approved for the treatment of clinically important hypotension occurring in the setting of anesthesia.
  • We look forward to partnering with XGen DJB given their extensive track record of successfully commercializing injectable products in the hospital setting, said Sean Brynjelsen, CEO of Eton Pharmaceuticals.
  • We are delighted to be teaming up with Eton as the commercial partner in introducing their ready-to-use Rezipres product, which is the first FDA-approved hydrochloride-based ephedrine injectable formulation, added Edmund Vanderbeck, President of XGen Pharmaceuticals DJB.

Athena Bioscience Announces Launch of Nexiclon™ XR, the Only Once-Daily Clonidine Extended-Release Tablets for Treatment of Hypertension

Retrieved on: 
Thursday, March 3, 2022
Ketan, Myocardial infarction, Risk, Conditional sentence, Patient, Approved Drug Products with Therapeutic Equivalence Evaluations, Cosmo, Anau, Quality of life, Heart failure, GA, Cardiovascular disease, LLC, BP, IM, Cohort study, Adherence (medicine), Athena, Compliance, Orange Book, Medicine, Tris, CEO, Medical Care (journal), Stroke, ADHD, Meta-analysis, Technology, Clonidine, Food and Drug Administration, Hypertension, Santino Di Matteo, Pharmaceutical industry, Medical device

"The launch of Nexiclon XR demonstrates Tris' continued success bringing differentiated technology-based medications to market," said Tris CEO Ketan Mehta.

Key Points: 
  • "The launch of Nexiclon XR demonstrates Tris' continued success bringing differentiated technology-based medications to market," said Tris CEO Ketan Mehta.
  • "Given their proven track record, we are delighted that Athena is our partner, launching this important cardiovascular product."
  • Nexiclon is based on Tris's LiquiXRdrug delivery technology, which has led to the development of multiple first-in-category products.
  • Athena Bioscience, LLCis a specialty pharmaceutical company that seeks to enhance medical options for both healthcare professionals and patients through innovative solutions to unmet challenges.

Clonidine (CAS 4205-90-7) Global Market Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Monday, December 13, 2021
Health, Pharmaceutical, CAS, Industry, Renewable energy, Explosive, Clothing, Fine chemical, Clonidine

The "Clonidine (CAS 4205-90-7) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Clonidine (CAS 4205-90-7) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.
  • This global report is a result of industry experts' diligent work on researching the world market of Clonidine.
  • The fifth chapter deals with Clonidine market trends and forecast, distinguish Clonidine manufacturers and suppliers.
  • The Clonidine global market report key points:

Monopar Therapeutics Reports Third Quarter 2021 Financial Results and Recent Clinical Developments

Retrieved on: 
Friday, November 12, 2021
Quality of life, VOICE, Cancer, Private Securities Litigation Reform Act, G&A, Therapy, Mucositis, Drug discovery, Clinical trial, CRT, SOM, Heart, IND, Security (finance), Food, COVID-19, Research, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Oropharyngeal cancer, Patient, Company, Liu v. Securities and Exchange Commission, GLOBE, Hydrogen chloride, SEC, Doxorubicin, Clonidine, Life, Chemoradiotherapy, FDA, Pharmaceutical industry, Lithium

WILMETTE, Ill., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced third quarter 2021 financial results and summarized recent clinical developments.

Key Points: 
  • First Patients Dosed in Camsirubicin Phase 1b Clinical Trial in U.S.
    WILMETTE, Ill., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced third quarter 2021 financial results and summarized recent clinical developments.
  • In September 2021, Monopar initiated the Phase 1b clinical trial, and in October 2021, dosed the first patients.
  • Monopar continues to work on activating additional clinical sites in the U.S. for the Phase 1b clinical trial.
  • Results for the Third Quarter Ended September 30, 2021, Compared to the Third Quarter Ended September 30, 2020
    Cash and cash equivalents as of September 30, 2021, were $22.3 million.